United Therapeutics (UTHR) Q1 2026 Earnings
United Therapeutics reported Q1 2026 revenue of $781.5M (-1.6% YoY), missed analyst consensus of $797.4M by $15.9M. Diluted EPS came in at $5.82 (-12.2% YoY), missed the $7.00 consensus by $1.18. United Therapeutics reports across 3 business segments, led by Pulmonary Hypertension and Rare Disease Therapies, Oncology, and Organ Manufacturing and Transplantation.
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about United Therapeutics's Q1 2026 earnings report.
United Therapeutics (UTHR) reported Q1 2026 earnings on May 6, 2026 before market open.
United Therapeutics reported revenue of $781.5M and diluted EPS of $5.82 for Q1 2026.
Revenue missed the consensus estimate of $797.4M by $15.9M. EPS missed the consensus estimate of $7.00 by $1.18.
Compared to the same quarter a year prior, revenue declined 1.6% from $794.4M a year earlier and diluted EPS declined 12.2% from $6.63.
You can read the 8-K earnings release (0001082554-26-000021) and the 10-Q periodic report (0001082554-26-000020) directly on SEC EDGAR. The filing index links above go to sec.gov.